MONOCYTE-DERIVED DENDRITIC CELLS ISOLATION AND PHENOTYPIC CHARACTERIZATION

Reda A. Suef, Ezz Elden Mahmoud Mohamed, Mohamed T. M. Mansour, Mohamed M. S. Farag

1,2,4 Department of Botany and Microbiology, Faculty of Science, Al-Azhar University, Cairo, Egypt,

3 Children’s Cancer Hospital and national cancer institute, Cairo, Egypt.

Corresponding author: mohamed.farag@azhar.edu.eg

ABSTRACT

Dendritic cell (DC) is the most powerful inducers and regulators of immune responses, responsible for interaction within the immune system. The ability of DC to induce or regulate/suppress immune responses led to attention in their immunotherapeutic use in various disease types. The aim of the presented study was to generate in vitro CD14+ enriched peripheral blood monocytes (PBMCs) following the culture with human monocyte-derived dendritic cell serum-free differentiation media over ten days with phenotypical analysis and morphological identification for functional studies. In vitro, peripheral blood of human donors samples were collected for the purification of blood CD14+ monocytes that represent the most common origin for DC precursors based on ficoll density gradient separation and human monocyte-derived dendritic cell enriched differentiation medium. After PBMCs isolation, the cell viability, cell yield were determined, the monocyte-derived dendritic cell surface marker expression was detected by flow cytometric analysis after staining with specific fluorescence-conjugated monoclonal antibodies. in vitro culture and differentiation of human monocytes into DCs and their subsequent maturation into mature DC constitute a critical first step for different downstream analysis ranging from an understanding of both human DC biology and function to their use in clinical diagnostics and therapeutic design for different disease.

Keywords: Monocyte; Dendritic cell; APCs, antigen-presenting cells; Ficoll density gradient separation.
Introduction.

Dendritic cells (DCs) are the most professional antigen-presenting cells (APC) of the mammalian immune system that represent a key mediator of both innate and adaptive immune responses (Steinman, 2012). Due to their abilities to pathogen recognition, capturing and processing machinery, migratory capacity and cytokines production that promotes pathogen-specific effector T cell differentiation and activation, growing interest in their use in clinical approaches has been observed. (Soloff, 2010).

Currently, there are two principal cell populations of dendritic cells in humans: classical DC (cDC) derived from myeloid precursor cells, e.g. peripheral blood monocytes and plasmacytoid DC subset (pDC) originated from lymphoid precursor (Bol et al., 2016).

During development, immature DCs express specific pattern recognition receptors that serve as expression markers and allow for the capture and processing of foreign antigens following infection (Harman et al., 2013). Once activated, immature dendritic cell exhibit an increase in the expression of class II MHC and co-stimulatory molecules critical for effective antigen presentation to naïve T cells (Sabado et al., 2017). Cytokines produced by DCs can also promote the differentiation of CD4+ T helper cells as part of immune activation (Bol et al., 2019).

Human blood DCs populations originate from bone marrow precursors represents approximately 0.1 - 1% of circulating peripheral blood mononuclear cells (PBMCs) (Macri et al., 2018). Subsequently, their isolation in enough numbers and purity for functional studies is challenged by their scarcity and a lack of distinguishing markers (Lo, 2003). Hence, the main objective of this study is to generate in vitro immature dendritic cells from CD14+ peripheral blood monocytes (PBMCs) by means of a differentiation and maturation process induced by exogenous stimuli (Recombinant Human IL-4, Recombinant Human GM-CSF and Recombinant Human TNF-α ) with morphological determination and phenotypic identification of PBMC-derived TNF-α with morphological determination and phenotypic identification of PBMC-derived DCs following culturing in a defined period which represent a crucial step for studying the biology of DCs, their roles in immune responses, and their potential use as immunotherapeutic tool against both malignant cell antigens and infective microorganisms.

Materials and methods

A. Materials

1. Study group:

The study was conducted in children cancer Hospital from September 2018 to June 2019, Egypt. 15 ml of human whole blood was collected from 10 normal human donors ranging from 20-35 years old. all donors signed a written informed agreement for the study.
2. Chemicals and cell culture media:

Blood samples were collected from Ahmed Maher teaching hospital blood bank, Egypt, in a vacutainer containing Heparin as anti-coagulant (Greiner bio-one, Australia) and processed immediately within 2 hours of collection.

The protocol was optimised for the preparation of PBMCs from human blood through using Ficoll-Hypaque density gradient centrifugation in addition to using RPMI-10 complete medium (Gibco, United Kingdom) supplemented with penicillin/streptomycin (10 mg/ml), Glutamine (200 mM), 10% FCS, insulin and hydrocortisone.

*In vitro* culture and differentiation of human monocytes into dendritic cells DCs were achieved by using the Human Monocyte-derived Dendritic Cell Differentiation Kit (R&Dsystem, Minneapolis, MN, USA). This kit enables the generation of active mature DCs from human monocytes in 10 days (Amedei *et al.*, 2011; Sabado and Bhardwaj, 2010).

B. Methods

1. Generation of MoDCs from Freshly Isolated blood:

1.1 Protocol for PBMCs Isolation.

Protocol for dendritic cell generation started with isolation of peripheral blood monocytes (PBMCs) from fresh human whole blood (< 24 hours old) using Ficoll-Hypaque density gradient centrifugation (Gill, 2019). In brief with slight modifications, blood samples were diluted in 1x Balanced Salt Solution (Gibco, UK) at 1:1.4 ratio, 35 mL of diluted cell suspension (blood/PBS mixture) layered over 15 mL of Ficoll-Paque (GE Healthcare, Life Science, Sweden) in a 50 mL conical tube.

For separation of PBMCs from whole blood effectively, Ficoll/diluted blood mix was centrifuged at different speeds for optimization purposes. centrifugation at 1600 rpm (400xg) for 30 min at 20°C with no brakes was approved for further isolation based on PBMCs yield and viability, after centrifugation, four distinct layers were observed which consisted of plasma, peripheral blood mononuclear cells (PBMC), ficoll-paque solution and sedimented red blood cells (RBC) with granulocytes. Upper layer that contains the plasma and most of the platelets discarded, the buffy coat mononuclear cell layer (lymphocytes, monocytes, and thrombocytes) suspended in 5ml of 1x BSS buffer, centrifuged at 1800 rpm for 8 minutes. after centrifugation, RBC lysis was performed to obtain a pure monocyte population. (10X) RBC lysis buffer was prepared by adding 8.3g NH4Cl (Sigma, Germany), 1.0g KHCO3 (Sigma, Germany), 1.8ml of 5% EDTA (Sigma, Germany) in 1000 ml of sterile water. RBC lysis was performed once for 3min. The lysis process was stopped using a 1x BSS buffer and centrifuged at 1800 rpm for 5 min with no brakes. After centrifugation, PBMC washed twice in 5ml of 1x buffer. after the first wash, PBMC Centrifuged at 350 xg (1300 rpm for 8 min at room temperature while cells centrifuged at low speed 200 xg (1000 rpm for 10 min for platelet removal. Finally, the PBMC white pellet obtained, resuspended immediately in
RPMI-10 complete medium (Gibco, United Kingdom) for cells counting, purity and viability determination by trypan blue exclusion test.

1.2 Culturing and differentiation of human monocytes into dendritic cells DCs.

After PBMC isolation, 1x10⁶ PBMCs/mL resuspended, plated in RPMI-10 complete medium. Mononuclear Cells Incubated for 2 hours at 37°C, 5% CO₂ and >95% humidity. On day 0, the adherent cell fraction washed and the differentiation processes into PBMC-derived DCs started by the addition of Mo-DC Differentiation Medium (Medium allow for the efficient and reliable in vitro maturation of human Monocytes (hMo) into immature as well as fully mature CD14+ monocyte-derived Dendritic Cells moDCs) supplemented with human IL-4 (Huber et al., 2018) and human GM-CSF (Merad et al., 2013) and incubated for 3 days at 37 °C and 5% CO₂. On day 3, a medium change was performed by removing half of the media from the well and replenishing with the same volume of fresh differentiation medium. the cells incubated for an additional 2 days at 37 °C and 5% CO₂. On day 5, as in a previous step, the medium was changed, and the cells incubated for an additional 2 days. On day 7, (immature MoDCs stage) immature dendritic cells collected, centrifuged, resuspended, and counted. then immature MoDCs cells (1x10⁶ cells) proceeded for detection of cell surface marker CD11c expression by flow cytometry. The cells also examined microscopically for the determination of the morphology of the cells on day 7. To complete the MoDCs maturation process, dendritic cell maturation induced by addition recombinant human TNF-α (1X) to the cell suspension (Vopenkova et al., 2012). the cells incubated for an additional 3 days at 37°C and 5%CO₂. On day 10, CD14+ monoyte-derived DC maturation induced with addition of human TNF-α as maturation agent and incubation the cells at 37 °C and 5% CO₂ for an additional 3 days. On day 10, mature dendritic cells can be observed and are ready to be used in the desired application.

Results

1. Viability and morphology

Examination of cultured CD14+ enriched with human differentiation media over a 7-day (immature) or a 10-day (with maturation) period shows a variation in size and morphological appearance (Figure1). Typical yields of immature (at day 7) and mature (at day 10) DC are approximately 60% and 50% respectively of the starting cell number with viability degree 90%.
Figure 1 | Morphology of monocyte-derived Dendritic Cells (moDCs) cultured in Differentiation Media for 10 days: A) day 0, B) day 3, C) day 5, D) day 7. Immature moDCs appear as irregularly outlined cells, E) Day 10: mature monocyte-derived Dendritic Cell (moDC) with multiple dendrites like structures on the surface.

2 Monocyte-derived dendritic cell surface marker detection.

2.1 Gating strategy of dendritic cells isolate at 5ul APC-conjugated anti CD11c.

Initial gating on dot plot graph using forward and sideway scatters (FS/SS). Gating was specified to Monocytes expected region (D) then cells were examined on quadrant plot in CD11C APC were detected on X axis of the quadrant plot. DCs subsets were defined according to the surface markers expression as CD11C APC positive only. According to our strategy DCs population was in Lower Right (LR) quadrant of the plot, referred to by Purple color and named (F). Samples reintroduction to flow cytometry devise to assess purity after centrifugation and resuspending in 1ml PBS Percentage of DCs in MCs mixture regarding to 5ul concentration of monoclonal antibodies was 6.44%. (Figure 2).
Figure 2 | Illustrates Phenotype analysis for DCs and purity for DCs isolate at 5 µl of anti CD11c antibody[A] Dot plot for initial gating of monocytes region on FS/ SS with extending the gating region to include small and large sized monocytes (D); [B] Detection of DCs. DCs were defined as (CD11C APC positive only) .

2.2 Gating strategy of dendritic cells isolate at 10 µl APC-conjugated anti CD11c .

Initial gating on dot plot graph specified to monocytes expected region (D) then cells were examined on X axis CD11C APC of the quadrant plot. DCs subsets were defined as CD11C APC positive population in Lower Right (LR) quadrant of the plot, referred by orange color and named (G). Samples reintroduction to flow cytometry assess purity (Percentage of DCs in MCs mixture) after centrifugation and resuspending in 1ml PBS regarding to 10µl concentration of monoclonal antibodies was 3.88 %. (Figure 3).
Figure 3 illustrates phenotype analysis for DCs isolate and purity at 10µl of anti CD11c antibody[A] Dot plot for initial gating of monocytes region on FS/ SS with extending the gating region to include small and large sized monocytes (D); [B] Detection of DCs. DCs were defined as (CD11C APC positive only).

Discussion

Dendritic cell (DC) are critical regulator of the innate and adaptive immune responses since they are present in different subsets, as either resident or migrating cells, in lymphoid and non-lymphoid organs (Macri et al., 2018). Currently, studies on mouse DC outnumber those on human cells (Cavalieri et al., 2010), however, the comparison between mouse and human models has been slightly misleading due to the basic biological and practical differences between the two models since many experiments performed in the mouse models are difficult to corroborate in humans. Thus, some of the assumptions made about human DC are turned from small animal experiments that have not been confirmed in man and may not necessarily apply (Ju, 2010). moDCs are a subset of DCs widely used in immunological studies as a convenient and easy approach after isolation of mononuclear cells directly from circulation (Fol et al., 2016). Also, using of moDCs instead of CD34+ derived DCs precursor is preferable this is due to the limited number of CD34+ precursors that can be isolated from apheresis products (Sabado and Bhardwaj, 2010). As such, the present study was conducted for generation and phenotypic characterization of human moDCs in vitro from peripheral blood CD14+ monocytes.

The generation of moDCs from a human is a multistep process. Firstly, DC precursors must obtain from the host. Although blood or bone marrow may serve as the initial source, PBMCs are the most common origin (Constantino et al., 2017; Itoh et al., 2002). The present study has used (with minor modification) Ficoll-based purification of mononuclear cells (CD14+ monocytes) from whole blood to serve as a precursor for DCs
(Gill, 2019). For maximum reproducibility of separation, only freshly isolated blood samples (2-4 hours after collection) were used for isolation to ensure high viability of PBMC, blood samples were also diluted in 1x PBS at 1:1.4 ratio to reduce RBC aggregation as well as freeing trapped PBMC, the volumetric ratio of sample to Ficoll was 3:7. Ficoll/diluted blood mix centrifuged at various speeds with optimal centrifugation at 1600 rpm (400xg) for 30 min at 20°C with no brakes based on PBMCs yield (ranges between 0.5-3 x 10^6 cells per mL blood) with efficient RBC removal, optimal centrifugation temperature of 20°C gives optimal results since higher temperatures (37°C) enhance RBC aggregation with yield reduction of the mononuclear cell count, while lower temperatures (4°C) inhibit aggregation, decreasing purity. to remove platelets from the mononuclear cell fraction, PBMC Centrifuged at low speed 200 xg (1000 rpm for 10 min).

After obtaining the precursor cells (CD14+ monocytes) From 10 individual PBMC samples healthy blood, PBMC are plated in 6 well plate (1 x 10^6 cells per well) to expand and differentiate. PBMCs initially cultured in differentiation medium supplemented with granulocyte monocyte colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4). This induces the “immature” DC phenotype. The immature cells subjected to a further differentiation step, to generate the “mature” DC by supplements the medium with tumor necrosis factor α (TNF-α). The process of generation typically takes 7 days to generate immature DCs, and another 3 days to generate mature DCs (Amedei et al., 2011; Nicolette et al., 2007). Morphology of immature moDC cultured in differentiation media in day 7 appear as irregularly outlined cells, while mature monocyte-derived Dendritic Cell (moDC) in day10 appears with multiple dendrites like structures on the surface.

Following culture in monocyte-derived differentiation media, day 7 monocyte-derived Dendritic Cell (moDC) stained with different concentration of aspecific anti CD11 monoclonal antibody. Stained cells were analyzed by using FACSCalibur™ to evaluate immuno-phenotype form of moDC. Also, to assess the purity of dendritic cells in the sample. at day7, FACS analysis demonstrates a typical CD11c+ve cells monocyte-derived Dendritic Cell (moDC) with a density 5210 cells/ml represents a purity percentage 6.44% at concenteration 5µl of APC-conjugated anti CD11c .While staining the monocyte-derived DC with 10µl of APC-conjugated anti CD11c demonstrates CD11c+ive moDC with a density 3820 cells/ml represents purity percentage 3.88% which indicate that the lower concentration of APC-conjugated anti CD11c was favorable at staining with more cell density and purity than higher concentration. Continuing culture of moDC in adifferential medium supplemented with a human TNF-α as maturation promoting factor for additional 3 days (day10) induce the cell maturation that demonstrated an increase in size and acquire unique morphological appearance with multiple cytoplasmic projections on the moDC surface when compared to their precursor cells such as monocytes or the morphology at day 7 which subsequently ready to be used in downstreaming desired application as in in the development of cancer immunotherapies as well as the treatment of autoimmune diseases.
In conclusion:

This study provides one of the approaches used to generate and characterize of human DC in vitro from peripheral blood CD14+ monocytes by using differentiation and maturation promoting factor (GMCSF, IL-4 and TNF-α) in 10 days. Although ex vivo methods have been developed for generating DCs, there is no current acclamation on the optimal ex vivo method. This is an important issue for future research to direct compare all these methods of DC generation. Also studying of ex vivo-generated monocyte-derived DCs stimulation to antigen-specific T cell responses at different aspects is also needed to be developed.

REFERENCES:

Amedei, A., Benagiano, M., della Bella, C., Niccolai, E., & D'Elios, M. M. (2011). Novel immunotherapeutic strategies of gastric cancer treatment. BioMed Research International, 2011.

Banchereau J, Palucka AK. (2005): Dendritic cells as therapeutic vaccines against cancer. Nature Reviews Immunology, 5(4):296-306.

Bol, K. F., Schreibelt, G., Gerritsen, W. R., De Vries, I. J. M., & Figdor, C. G. (2016). Dendritic cell–based immunotherapy: state of the art and beyond.

Bol, K. F., Schreibelt, G., Rabold, K., Wculek, S. K., Schwarze, J. K., Dzionek, A., ... & Neyns, B. (2019). The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. Journal for immunotherapy of cancer, 7(1), 109.

Cavalieri, D., Rivero, D., Beltrame, L., Buschow, S. I., Calura, E., Rizzetto, L., ... & Bonaiuti, R. (2010). DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome research, 6(1), 10.

Constantino, J., Gomes, C., Falcão, A., Neves, B. M., & Cruz, M. T. (2017). Dendritic cell-based immunotherapy: a basic review and recent advances. Immunologic research, 65(4), 798-810.

Fol, M., Nitecka-Blaźlak, A., Szpakowski, P., Madiraju, M. V., Rudnicka, W., Druszczynska, M., ... & Kowalewicz-Kulbat, M. (2016). Evaluation of two different dendritic cell preparations to BCG reactivity. Archives of Biological Sciences, 68(2), 263-271.

GILL, P. K. (2019). Rapid Isolation of Peripheral Blood Mononuclear Cells from Whole Blood with Ficoll Hypaque Density Centrifugation. Journal of International Research in Medical and Pharmaceutical Sciences, 17-20.

Harman, Andrew N., Chris R. Bye, Najla Nasr, Kerrie J. Sandgren, Min Kim, Sarah K. Mercier, Rachel A. Botting, Sharon R. Lewin, Anthony L. Cunningham, and Paul U. Cameron. (2013): "Identification of lineage relationships and novel markers of blood and skin human dendritic cells." The Journal of Immunology 190, no. 1: 66-79.
Huber, A., Dammeijer, F., Aerts, J. G., & Vroman, H. (2018). Current state of dendritic cell-based immunotherapy: opportunities for in vitro antigen loading of different DC subsets?. Frontiers in immunology, 9, 2804.

Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H. (2002): Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother. 51:99

Ju, X., Clark, G., & Hart, D. N. (2010). Review of human DC subtypes. In Dendritic Cell Protocols (pp. 3-20). Humana Press.

Lo, P. (2003). HIV hijacks dendritic cells. Nature medicine, 9(6), 650-650.

Macri, C., Pang, E. S., Patton, T., & O'Keeffe, M. (2018). Dendritic cell subsets. In Seminars in cell & developmental biology (Vol. 84, pp. 11-21). Academic Press.

Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013). The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annual review of immunology, 31, 563-604.

Nicolette, C. A., Healey, D., Tcherepanova, I., Whelton, P., Monesmith, T., Coombs, L., ... & Miesowicz, F. (2007). Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine, 25, B47-B60.

Ohnmacht C, Pullner A, King SBS, Drexler I, Meier S, Brocker T, Voehringer D. (2009): Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med, 206(3):549–59.

Pulendran, Tang, Hua, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I. Nakaya, Kousik Kundu, Niren Murthy, Thomas B. Kepler, Bernard Malissen, and Bali. (2010): "The T helper type 2 response to cysteine proteases requires dendritic cell–basophil cooperation via ROS-mediated signaling." Nature immunology 11, no. 7. 608.

Sabado, R. L., & Bhardwaj, N. (2010). Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy, 2(1), 37–56.

Sabado, R. L., Balan, S., & Bhardwaj, N. (2017). Dendritic cell-based immunotherapy. Cell research, 27(1), 74-95.

Soloff, A. C., & Barratt-Boyces, S. M. (2010). Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell research, 20(8), 872-885.

Steinman, R. M. (2012). Decisions about dendritic cells: past, present, and future. Annual review of immunology, 30, 1-22.
Vopenkova, K., Mollova, K., Buresova, I., & Michalek, J. (2012). Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. Journal of cellular and molecular medicine, 16(11), 2827-2837.

عزيز خلايا الدندروت المشتقة من وحيدات اللواد وتوصيف النمط الظاهري.

RSA Abd El Aziz, Sohia, 4، الدين محمود مفيد، 3، وweis منصور، 3، وweis منصور سعد فرج.

قسم علم النبات والكائنات الدقيقة، كلية العلوم، جامعة الأزهر، القاهرة، مصر.

مستقبل خلايا سرطان الأطفال والمعهد القومي للسرطان، القاهرة، مصر.

البريد الإلكتروني للباحث الرئيسي: (mohamed.farag@azhar.edu.eg).

الملخص العربي

يعتبر خلايا الدندروت واحد من أهم الخلايا الازمة لتنشيط وتنظيم الاستجابات المناعية، حيث تعتبر حلقة الوصل بين الاستجابة المناعية الفطرية والموتوسطة بالخلايا. أدت قدرة خلايا الدندروت على هذا / تنظيم/ قمع الاستجابات المناعية إلى الابتكار في استخدامها كأحد الآدوات القوية للعلاج المناعي في أنواع الأمراض المختلفة.

كان الهدف من هذه الدراسة المقدم هو إنتاج خلايا الدندروت عبر استقاءها من خلايا أحادية النوي في الدم المحيطي بعد استراقها باستخدام وسط التمدد الغذائي CD14+ enriched peripheral blood monocytes (PBMCs) تحتوي على عوامل تعزيز النضج ومتابعة النمو والتمدد على مدار عشرة أيام. تم تحديد النمط المظهري (من خلال الكشف على بعض المستقبلات السطحية للخلايا) والتعرف المورفولوجي لها. معتملا: تم جمع عينات الدم المحيطي من المبترين الأصحاء و ذلك تكثيف وتمديد الخلايا أحادية النوي (CD14+Ve) والتي تم تحليلها الأكثر شيوعا لسلائف الخلايا الدندروت، وذلك لاستخدام الفيوك للحصول على عوامل النمو والفيك المحدد في الشركة. تم استخدام وسط التمدد الغذائي لتوحيد خلايا الدندروت خلال فترة زمنية محددة. بعد عزل PBMCs وتجهيز الخلايا، تم الكشف أيضا عن وجود بعض المستقبلات السطحية هذه الخلايا الدندروت المشتقة من الخلايا الحادية النوي في وحيدات الثديية. التحليل النمو الفيوكوغرافي (flowcytometric analysis) لدراسة الخلايا الدندروت وحيدات الثديية والخلايا الحادية النوي، الزيادة في الببتيدات وحيدات الثديية.

أخيرا، يمكن ضبط عملية زراعة وتمديد الخلايا الأحادية النوي إلى أولي ساحة لمختلف التحديات المتتالية والتي تراوحو بين هم كل من بيولوجيا خلايا الدندروت البشرية ووظيفتها إلى استخدامها في التشخيص السريري وكذلك تصميم علاجات مناعية متخصصة لمختلف الأمراض.

الكلمات المفتاحية: الخلايا الأحادية النوي، الخلايا الدندروت، الخلايا السرطانية.